Your browser doesn't support javascript.
Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection.
Schäfer, Eik; Scheer, Christian; Saljé, Karen; Fritz, Anja; Kohlmann, Thomas; Hübner, Nils-Olaf; Napp, Matthias; Fiedler-Lacombe, Lizon; Stahl, Dana; Rauch, Bernhard; Nauck, Matthias; Völker, Uwe; Felix, Stephan; Lucchese, Guglielmo; Flöel, Agnes; Engeli, Stefan; Hoffmann, Wolfgang; Hahnenkamp, Klaus; Tzvetkov, Mladen V.
  • Schäfer E; Department of Clinical Pharmacology, Institute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, Greifswald, Germany.
  • Scheer C; Department of Anesthesiology, University Medicine Greifswald, Greifswald, Germany.
  • Saljé K; Department of Anesthesiology, University Medicine Greifswald, Greifswald, Germany.
  • Fritz A; Department of Clinical Pharmacology, Institute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, Greifswald, Germany.
  • Kohlmann T; Department of General Pharmacology, Institute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, 17489, Greifswald, Germany.
  • Hübner NO; Institute for Community Medicine, Section Epidemiology of Health Care and Community Health, University Medicine Greifswald, Greifswald, Germany.
  • Napp M; Central Unit for Infection Prevention and Control, University Medicine Greifswald, Greifswald, Germany.
  • Fiedler-Lacombe L; Institute of Hygiene and Environmental Medicine, University of Greifswald, Greifswald, Germany.
  • Stahl D; Departments of Emergency and Acute Medicine, University Medicine Greifswald, Greifswald, Germany.
  • Rauch B; Independent Trusted Third Party, University Medicine Greifswald, Greifswald, Germany.
  • Nauck M; Independent Trusted Third Party, University Medicine Greifswald, Greifswald, Germany.
  • Völker U; Department of General Pharmacology, Institute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, 17489, Greifswald, Germany.
  • Felix S; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.
  • Lucchese G; DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany.
  • Flöel A; Department of Functional Genomics, University Medicine Greifswald, Greifswald, Germany.
  • Engeli S; DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany.
  • Hoffmann W; Department of Internal Medicine B, Cardiology, Pneumology, Infectious Diseases, Intensive Care Medicine, University Medicine Greifswald, Greifswald, Germany.
  • Hahnenkamp K; Department of Neurology, University Medicine Greifswald, Greifswald, Germany.
  • Tzvetkov MV; Department of Neurology, University Medicine Greifswald, Greifswald, Germany.
Sci Rep ; 12(1): 7249, 2022 05 04.
Article in English | MEDLINE | ID: covidwho-1890245
ABSTRACT
We analyzed symptoms and comorbidities as predictors of hospitalization in 710 outpatients in North-East Germany with PCR-confirmed SARS-CoV-2 infection. During the first 3 days of infection, commonly reported symptoms were fatigue (71.8%), arthralgia/myalgia (56.8%), headache (55.1%), and dry cough (51.8%). Loss of smell (anosmia), loss of taste (ageusia), dyspnea, and productive cough were reported with an onset of 4 days. Anosmia or ageusia were reported by only 18% of the participants at day one, but up to 49% between days 7 and 9. Not all participants who reported ageusia also reported anosmia. Individuals suffering from ageusia without anosmia were at highest risk of hospitalization (OR 6.8, 95% CI 2.5-18.1). They also experienced more commonly dyspnea and nausea (OR of 3.0, 2.9, respectively) suggesting pathophysiological connections between these symptoms. Other symptoms significantly associated with increased risk of hospitalization were dyspnea, vomiting, and fever. Among basic parameters and comorbidities, age > 60 years, COPD, prior stroke, diabetes, kidney and cardiac diseases were also associated with increased risk of hospitalization. In conclusion, due to the delayed onset, ageusia and anosmia may be of limited use in differential diagnosis of SARS-CoV-2. However, differentiation between ageusia and anosmia may be useful for evaluating risk for hospitalization.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ageusia / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Humans / Middle aged Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-11103-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Ageusia / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Humans / Middle aged Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-11103-0